Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXN Addex Therapeutics	$8.96 +1.7%	$8.22	$6.51 ▼ $13.27	$9.33M	1.62	94,414 shs	60,692 shs
ESLA Estrella Immunopharma	$0.88 -6.3%	$1.00	$0.63 ▼ $3.23	$34M	0.37	126,505 shs	7,109 shs
LVTX LAVA Therapeutics	$1.31 +0.4%	$1.30	$0.85 ▼ $2.39	$34.33M	0.48	154,731 shs	11,959 shs
XLO Xilio Therapeutics	$0.68 -0.6%	$0.77	$0.62 ▼ $1.70	$35.19M	-0.01	1.42 million shs	345,928 shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXN Addex Therapeutics	+1.07%	+0.91%	+12.08%	+14.72%	+12.28%
ESLA Estrella Immunopharma	-6.28%	-11.01%	-9.18%	-7.17%	-4.24%
LVTX LAVA Therapeutics	+0.38%	0.00%	-0.76%	+1.55%	-29.19%
XLO Xilio Therapeutics	-0.62%	-1.92%	-27.92%	-9.48%	-25.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADXN Addex Therapeutics	2.9284 of 5 stars	3.5	5.0	2.1	0.8	0.6
ESLA Estrella Immunopharma	2.5842 of 5 stars	3.5	3.0	3.3	1.7	0.0
LVTX LAVA Therapeutics	2.2369 of 5 stars	3.0	5.0	3.3	0.0	0.0
XLO Xilio Therapeutics	3.6375 of 5 stars	3.5	5.0	3.3	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADXN Addex Therapeutics	3.00	Buy	$30.00	234.82% Upside
ESLA Estrella Immunopharma	3.00	Buy	$16.00	1,716.12% Upside
LVTX LAVA Therapeutics	2.00	Hold	$3.17	141.73% Upside
XLO Xilio Therapeutics	3.00	Buy	$4.00	492.33% Upside

Current Analyst Ratings Breakdown

Latest ADXN, ESLA, XLO, and LVTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	ESLA Estrella Immunopharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
5/15/2025	LVTX LAVA Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
3/31/2025	LVTX LAVA Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$1.50 ➝ $1.50

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADXN Addex Therapeutics	$460K	20.65	N/A	N/A	$10.37 per share	0.86
ESLA Estrella Immunopharma	N/A	N/A	N/A	N/A	$0.12 per share	N/A
LVTX LAVA Therapeutics	$11.98M	2.88	N/A	N/A	$1.06 per share	1.24
XLO Xilio Therapeutics	$6.34M	5.52	N/A	N/A	$0.40 per share	1.69

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADXN Addex Therapeutics	$8.02M	-$0.34	N/A	∞	N/A	3,584.49%	-54.27%	-49.15%	9/1/2025 (Estimated)
ESLA Estrella Immunopharma	-$7.31M	-$0.26	N/A	∞	N/A	N/A	-1,132.38%	-273.91%	N/A
LVTX LAVA Therapeutics	-$25.11M	-$1.04	N/A	N/A	N/A	N/A	-86.38%	-34.12%	8/19/2025 (Estimated)
XLO Xilio Therapeutics	-$58.24M	-$0.84	N/A	N/A	N/A	-585.54%	-262.69%	-64.01%	8/14/2025 (Estimated)

Latest ADXN, ESLA, XLO, and LVTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	LVTX LAVA Therapeutics	-$0.37	-$0.13	+$0.24	-$0.13	N/A	N/A
5/13/2025	Q1 2025	XLO Xilio Therapeutics	$0.10	-$0.18	-$0.28	-$0.18	$42.00 million	$2.93 million
3/28/2025	Q4 2024	LVTX LAVA Therapeutics	-$0.32	-$0.14	+$0.18	-$0.14	$2.40 million	$2.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADXN Addex Therapeutics	N/A	N/A	N/A	N/A	N/A
ESLA Estrella Immunopharma	N/A	N/A	N/A	N/A	N/A
LVTX LAVA Therapeutics	N/A	N/A	N/A	N/A	N/A
XLO Xilio Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADXN Addex Therapeutics	N/A	3.02	4.42
ESLA Estrella Immunopharma	N/A	0.22	0.22
LVTX LAVA Therapeutics	N/A	6.73	6.73
XLO Xilio Therapeutics	N/A	1.96	1.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADXN Addex Therapeutics	16.14%
ESLA Estrella Immunopharma	0.35%
LVTX LAVA Therapeutics	N/A
XLO Xilio Therapeutics	54.29%

Insider Ownership

Company	Insider Ownership
ADXN Addex Therapeutics	15.00%
ESLA Estrella Immunopharma	55.10%
LVTX LAVA Therapeutics	9.50%
XLO Xilio Therapeutics	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADXN Addex Therapeutics	30	1.06 million	901,000	Not Optionable
ESLA Estrella Immunopharma	N/A	36.17 million	16.24 million	Not Optionable
LVTX LAVA Therapeutics	60	26.31 million	23.81 million	Optionable
XLO Xilio Therapeutics	70	51.78 million	49.09 million	Not Optionable

ADXN, ESLA, XLO, and LVTX Headlines

Recent News About These Companies

James Samuel Shannon Acquires 25,000 Shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) Stock

June 19, 2025 | insidertrades.com

Xilio Therapeutics expands board, elects new director

June 12, 2025 | investing.com

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to Board of Directors

June 10, 2025 | quiverquant.comQ

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors

June 10, 2025 | globenewswire.com

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

June 5, 2025 | globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 3, 2025 | globenewswire.com

Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering

June 2, 2025 | globenewswire.com

Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite ...

June 2, 2025 | stockhouse.com

Xilio Therapeutics, Inc. Announces Proposed Underwritten Public Offering of Pre-Funded Warrants and Series A, B, and C Warrants

June 2, 2025 | quiverquant.comQ

Xilio Therapeutics Announces Proposed Public Offering

June 2, 2025 | globenewswire.com

Xilio Therapeutics, Inc. (XLO) Reports 26% Response in Colon Cancer Drug Trial

May 31, 2025 | insidermonkey.com

Xilio Therapeutics Reports Preliminary 26% Objective Response Rate in Phase 2 Trial of Vilastobart Combined with Atezolizumab for Metastatic MSS Colorectal Cancer

May 31, 2025 | quiverquant.comQ

Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

May 31, 2025 | globenewswire.com

Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results

May 8, 2025 | finanznachrichten.de

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results

May 8, 2025 | finance.yahoo.com

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results

May 8, 2025 | globenewswire.com

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 2, 2025 | globenewswire.com

Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting

April 23, 2025 | globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 4, 2025 | globenewswire.com

Xilio Therapeutics reports Q4 EPS (20c) vs (64c) last year

March 11, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Rivian vs. Lucid: Who’s Best Positioned to Steal Tesla’s Thunder?
By Nathan Reiff | June 20, 2025
View Rivian vs. Lucid: Who’s Best Positioned to Steal Tesla’s Thunder?
5 Stocks Set to Soar This Summer
By Ryan Hasson | June 2, 2025
View 5 Stocks Set to Soar This Summer
Tesla: The Next Month Could Make or Break the Year
By Sam Quirke | June 27, 2025
View Tesla: The Next Month Could Make or Break the Year
Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides
By Leo Miller | June 25, 2025
View Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides
Tesla Stock Dips to Buy Zone—Robotaxi Catalyst Ahead?
By Gabriel Osorio-Mazilli | June 9, 2025
View Tesla Stock Dips to Buy Zone—Robotaxi Catalyst Ahead?

ADXN, ESLA, XLO, and LVTX Company Descriptions

Addex Therapeutics NASDAQ:ADXN

$8.78 -0.03 (-0.39%)

As of 06/27/2025 04:00 PM Eastern

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Estrella Immunopharma NASDAQ:ESLA

$0.88 -0.06 (-6.28%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.90 +0.01 (+1.59%)

As of 06/27/2025 07:04 PM Eastern

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

LAVA Therapeutics NASDAQ:LVTX

$1.31 +0.01 (+0.38%)

Closing price 06/27/2025 03:55 PM Eastern

Extended Trading

$1.32 +0.01 (+0.76%)

As of 06/27/2025 04:04 PM Eastern

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

Xilio Therapeutics NASDAQ:XLO

$0.68 0.00 (-0.62%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.68 +0.00 (+0.70%)

As of 06/27/2025 07:48 PM Eastern

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time